iBioIBIO
Recorded

iBio 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanSenior Research Analyst and Managing Director

Thanks, everyone, again for joining us for this year's Guggenheim Healthcare Innovation Conference on day two here today. Vamil Divan, one of the biopharma analysts here from Guggenheim, joined on the Guggenheim side up here on stage by Daniel Krizay from the team. Next in this room, very pleased to have the iBio team. Next to myself, I have Martin Brenner, the CEO and CSO, and Felipe Duran, who's the CFO. Thanks so much for joining us again. You were here last year, 12 months ago. It's been a pretty productive time for the company in the prior 12 months. Maybe you can just give an overview for those less familiar with the company on the iBio story and the progress you've made over these last 12 months, including becoming a clinical-stage company now.

Martin BrennerCEO and Chief Scientific Officer

Perfect. Felipe, do you want to- Sure want to take that?

Felipe DuranCFO

Thank you, Martin. You hit it on the nose, right? We became a clinical-stage company this year, and I think that's the major milestone. We took myostatin into the clinic. We've completed the SAD study, and we're planning to read that out in the first quarter of next calendar year. The other things that we've done over the last 12 months is we've advanced our portfolio, right? Activin E is now basically getting ready to get approved in Australia, and we hope to be dosing patients in the first quarter of next year. Our IBIO-800 molecule is way into CMC and toxicology, and we're planning to file that in Australia sometime in the summer of next year. Also, we've made strides on our amylin molecule, right? We've mentioned in the past that we're the only company that can interrogate a DACRA, SARA, R1 receptor, and R3 receptor.

Felipe DuranCFO

The only reason we have been able to do that is we have also advanced our platform, right? Now we have GPCR technology, we have cryo-EM technology, and we are able to then interrogate these molecules further and actually not go blind, right, when we are developing and discovering these assets. Lastly, we have strengthened our balance sheet, right? in January of last year, we brought Frazier in a PIPE, and that allows us to now extend our cash runway, which gets us into the second quarter of 2028 calendar year. We have multiple inflection points, and I know you will ask that Yeah in a little bit, but we have got multiple inflection points that that cash can drive.

Vamil DivanSenior Research Analyst and Managing Director

Okay. All right, great. Thanks for the overview, and obviously a lot of programs to kind of go through this morning. Maybe let us start on the 610, the Activin E. You did present some additional non-human primate data at EASD. What was your key takeaways from that data presentation, and how do they inform what you are looking to do on the clinical side?

Martin BrennerCEO and Chief Scientific Officer

Our IBIO-610 program is an Activin E antibody. We are still, to this day, the only company with an antibody against the target. There is obviously liver knockdown pursued by multiple companies right now, but we feel like with an antibody, we have a few points of differentiation against those. We have started the non-human primate study because we were not convinced that the mouse data would translate into humans, and at that time, there was no human data. What we found in the monkey study was actually that the monkey model is quite translational. That was the first finding. The body composition data was a little anticlimactic because it is exactly reproducing what we see in humans now, which is good.

Martin BrennerCEO and Chief Scientific Officer

What we have shown two weeks, three weeks ago at EASD, the European Diabetes Meeting, is that if you combine a GLP-1 and aggressively lose weight in these monkeys and you add an Activin E on top of that, you basically shift your body weight loss from 10%, 20% muscle to almost exclusively fat. This weight loss almost exclusively came out of fat, and obviously, we want to retain muscle, we want to retain bone density. The one tissue that makes us all sick is visceral fat and fat tissue in general, and that is what this is actually reducing. That data set is not complete. This Saturday, we are going to show body weight data, which is, we ran this monkey study all the way out to 28 weeks, and that is going to be enlightening because of the mechanism, and it explains a little bit better what this mechanism does.

Martin BrennerCEO and Chief Scientific Officer

I think a lot of people get confused with Activin E. It is not a GLP-1. It is not reducing your food intake. It is actually directly working on fat tissue, which takes a lot more time to actually have an effect. There is also this massive benefit that not a lot of people need to lose 40% of their body weight, and they probably should not take a GLP-1, or if you will, in the hardest case, a retatrutide. They might actually be much, much better off with something that slowly reduces fat mass and actually retains muscle completely. That monkey study should be eye-opening, and hopefully it will go very nicely with the clinical phase II data we are expecting from Arrowhead and Wave over the next few quarters. That is going to be really interesting how these studies and species actually compare.

Vamil DivanSenior Research Analyst and Managing Director

Yeah. Okay, great. I think you mentioned you are on track now to file in Australia by year end, first in human data first half of next year. Maybe you can just share with us what we should expect from the study, what should it look like, and then when we get to that interim, what is going to be the key things to look at?

Martin BrennerCEO and Chief Scientific Officer

Yeah. First of all, I know there is always this pressure in obesity to show nearly phase III level endpoints on obesity.

Martin BrennerCEO and Chief Scientific Officer

Sure. I would just want to highlight that phase I-A is a safety study and a PK study.

Martin BrennerCEO and Chief Scientific Officer

This is a long-acting antibody. We intend to dose this very infrequently. The most important thing is to correlate the dose we give, the inhibition of the pathway we see, because that's going to be an important differentiator for an antibody. We have shown we can block this pathway completely, not just about 85%. The third thing obviously will be we're going to take body composition images. We have enrolled this time in our first study in myostatin, we took patients that were just overweight. This time, we're really taking obese patients in, so we will do body composition scans. The study's not long enough to really show body weight loss.

Martin BrennerCEO and Chief Scientific Officer

We already know that, but we want to see, are we going directionally in the right direction with this antibody? Most importantly, it's really a safety and a PK study, with the added benefit that we see early on signs of efficacy.

Vamil DivanSenior Research Analyst and Managing Director

Okay. You mentioned Arrowhead and Wave. They showed some data this year. What did you learn from what they shared, especially in terms of this relationship, as you talked about, between visceral fat Yeah total weight loss, and how is it impacting how you think about developing your program?

Martin BrennerCEO and Chief Scientific Officer

Yeah. I think it is very important if you have a new mechanism. If you are the first one going in the clinic, you are kind of blind. You do not know what you do not know yet. We are eternally grateful to Wave and Arrowhead to kind of pave a little bit of a path. We have learned specifically from Arrowhead that type 2 diabetic patients that are obese and they are typically resistant to GLP-1 treatment probably have a much better response to GLP-1 if you add an Activin E. Say you can double the weight loss in a type 2 diabetic, that is really, really meaningful. The mechanism also might play a role in can we influence how the progression of type 2 diabetes happens? Most type 2 diabetics, if they actually get to a certain age, will have complications like diabetic foot ulcers, diabetic nephropathy, retinopathy, neuropathy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day